The importance of life sciences companies focused on rare diseases to take early steps to bridge connections with patients, caregivers, and healthcare providers.
Mary Anne Greenberg
Advertisement
Articles by Mary Anne Greenberg
Therapeutic companies that work with rare diseases must take early steps to build relationships with patients, caregivers, and HCPs.
With the role of Medical Information in pharma companies changing in recent years, this article outlines some current and future trends including globalization and the use of data to drive change.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Pfizer Receives Unsolicited Mini-Tender Offer for 1 Million Shares from Tutanota: Report
2
Pharma M&A Roundup: Novartis to Acquire Pan-Mutant-Selective PI3Kα Inhibitor from Synnovation Therapeutics, Collegium to Acquire Azstarys from Corium Therapeutics
3
How Do Recent Actions from FDA Provide Insight to the Agency's Enforcement Posture?
4
Pharmaceutical Executive Daily: Pfizer Warns Shareholders to Reject Mini-Tender Offer
5